BioCurex, Inc.(fka BOCX)

[fluffy]

How long shall we wait for news from Abbott?

Abbotts initial step will be to integrate the test into their achitect screening system. How long will this take? It is difficult to say but we can get a little guidance from another company that went trough the same procedure.
Diagnocure made a license deal with Geneprobe the 20th Nov 2003. And it took Geneprobe about 10½ months to complete the integration into their Aptima platform. (Pr. the 28th Sep 2004 see below).
If we follow these ruff guidelines we are looking at mid February +/- a month or 2 for Abbots Achitect integration. We are still not sure though, whether Abbott will allow such an announcement to be made, but I would imaging they would as they are not competing with any other company on the RECAF technology at this point.
Once intergration has been completed they will need to test a fair amount of samples and then submit to the FDA for approval. ( I recken they would begin with some of the most widespread cancer forms like prostate, lung and breast) The sampling and writing of the report for FDA submission should be relative quick (3-5 months I imagine) and the FDA answer would typically take about 3-6 months. (perhaps here it it would be an advantage to be a pharma mammoth like Abbott)
The conclusion is that these things take time, but we should be much closer to commercialisation than 9 month ago. Hopefully we will get an update from Abbott soon!!

And lets not forget that BOCX in their latest update said that they are still in negociations with other pharmas some equally large as Abbott. My position is that if Abbott was interested others are probably also, and I think we have a good chance of seeing other deals near term.

Interestingly our data on prostate are quite a bit better than Diagnocures/Geneprobes PCA3 test, which comes in at a sensitivity/specificity of 66/75. BOCX,es data on prostate is 88/100. (high specificity is extremely important for mass screening, avoiding costly (money and emotional) false positives. If Geneprobe was to mass screen say 100.000 persons with the PCA3 test at current cut-of levels they would have to tell 25.000 people they possible have cancer even though they probably have’nt).

http://www.diagnocure.com/anglais/section1/sec14.asp
09.28.2004 Dianocure PR
As regards the PCA3 prostate cancer project, Henry L. Nordhoff, Chairman, President and CEO of Gen-Probe Inc.,
recently noted that they had successfully transferred DiagnoCure’s first generation PCA3 assay onto the
Company’s APTIMA technology platform and that the development work is proceeding well.